XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2021
Oct. 03, 2021
Sep. 27, 2020
Oct. 03, 2021
Sep. 27, 2020
Loss Contingencies [Line Items]          
Unrealized gain (loss) on equity securities [1]   $ 322 $ (68) $ 1,518 $ 391
Certain legal matters, net [2]   38 (17) 458 5
IPR&D [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charge     900   900
EpiPen [Member]          
Loss Contingencies [Line Items]          
Certain legal matters, net $ 345     345  
BioNTech and Cerevel Therapeutics, LLC [Member]          
Loss Contingencies [Line Items]          
Unrealized gain (loss) on equity securities   $ 420   1,500  
Allogene and BioNTech [Member]          
Loss Contingencies [Line Items]          
Unrealized gain (loss) on equity securities         397
Allogene [Member]          
Loss Contingencies [Line Items]          
Unrealized gain (loss) on equity securities     (131)    
BioNTech [Member] | Collaborative Arrangement [Member]          
Loss Contingencies [Line Items]          
Proceeds from collaborators       $ 188  
Puma Technologies [Member] | Collaborative Arrangement [Member]          
Loss Contingencies [Line Items]          
Proceeds from collaborators         40
Eli Lilly & Company [Member] | Collaborative Arrangement [Member]          
Loss Contingencies [Line Items]          
Proceeds from collaborators         30
Disposed of by Sale [Member] | CK1 assets sold to Biogen, Inc [Member]          
Loss Contingencies [Line Items]          
Consideration transferred     $ 75   $ 75
[1] Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of October 3, 2021, there were cumulative impairments and downward adjustments of $95 million and upward adjustments of $151 million. Impairments, downward and upward adjustments were not significant in the third quarter and first nine months of 2021 and 2020.
[2] The first nine months of 2021 primarily includes an amount to resolve a Multi-District Litigation relating to EpiPen pending against the Company in the U.S. District Court for the District of Kansas for $345 million, which remains subject to court approval. See Note 12A5.